Opposing results of the monarchE and PALLAS trials investigating the role of adjuvant treatment with the CDK4/6 inhibitors abemaciclib and palbociclib, respectively, in patients with hormone receptor-positive, HER2-negative early stage breast cancer have recently been presented. Herein, potential reasons why these two drugs that have similar efficacy in the metastatic setting have produced disparate results in the adjuvant setting are discussed.
CDK4/6 inhibitors for HR+HER2− early stage breast cancer : When to escalate treatment? / G. Curigliano. - In: NATURE REVIEWS. CLINICAL ONCOLOGY. - ISSN 1759-4774. - 18:2(2021 Feb), pp. 67-68. [10.1038/s41571-020-00453-1]
CDK4/6 inhibitors for HR+HER2− early stage breast cancer : When to escalate treatment?
G. Curigliano
Conceptualization
2021
Abstract
Opposing results of the monarchE and PALLAS trials investigating the role of adjuvant treatment with the CDK4/6 inhibitors abemaciclib and palbociclib, respectively, in patients with hormone receptor-positive, HER2-negative early stage breast cancer have recently been presented. Herein, potential reasons why these two drugs that have similar efficacy in the metastatic setting have produced disparate results in the adjuvant setting are discussed.
| File | Dimensione | Formato | |
|---|---|---|---|
|
CDK 4-6 Nature 2021.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
682.81 kB
Formato
Adobe PDF
|
682.81 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
